Elvira Valera

Elvira Valera has extensive work experience in the field of biological studies and pharmaceutical research. Elvira started their career as a Research Associate at Universidad Miguel Hernandez in 2006, where they focused on investigating the molecular involvement of TRPV receptors in inflammation and pain. Elvira then moved to The Salk Institute for Biological Studies, where they worked as a Postdoctoral Fellow, utilizing stem cell and molecular biology methods to study endodermic differentiation and ion channel functionality.

In 2009, Valera joined the Joint Center for Biosciences as a Senior Research Associate, where they developed a new formulation of feeder-free stem cell culture medium and established a stem cell facility. Elvira returned to The Salk Institute as a Postdoctoral Research Associate in the same year, where they identified molecular targets of a novel small drug in in vivo and in vitro models.

Valera later joined UC San Diego as an Assistant Project Scientist, conducting analysis on microRNAs in multiple system atrophy and investigating anti-inflammatory drug repositioning. Elvira then moved to Celgene as a Scientist II, leading projects involving targeted approaches for neurodegenerative proteins and collaborating with various departments and external partners to build a strong neuroscience pipeline.

In 2019, Valera joined Escient Pharmaceuticals as a Scientist II, serving as a biology project leader in the study of specific orphan GPCRs and conducting cell-based assay development and animal model characterization for drug candidate selection and efficacy determination.

Currently, Valera is employed at Vividion Therapeutics, Inc. as a Senior Scientist, and later as a Principal Scientist. The specific details and responsibilities of these roles are not provided in the information given.

Elvira Valera holds a Ph.D. in Neurobiology from Universidad de Extremadura, where they studied from 2000 to 2006. Prior to that, they obtained a B.Sc. in Biology from the same institution, completing their undergraduate studies from 1995 to 2000.